John Lawler
CIK: 0002123720
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
CMMB
Chemomab Therapeutics Ltd.
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Lawler John
Lawler John (SEC CIK 0002123720) files insider reports with the SEC as Chief Development Officer of Chemomab Therapeutics Ltd. (CMMB).
Signal8 holds 1 ownership filing by Lawler John, a Form 3, filed on Apr 10, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Lawler John's filings is in TEL AVIV.
Other insiders filing for Chemomab Therapeutics Ltd. (CMMB)
- Cohen Neil Harris, Director
- Melincoff Gwen A, Director
- Mor George Adi, Chief Executive Officer
- Darvish Nissim, Director
- Moses Alan Charles, Director
- Fatal Sigal, Chief Financial Officer